Press Releases
-
Apr 25, 2019
- Total Revenues Top $400 million in the QuarterFinancial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended March 31, 2019 2018 % Change Total Revenues $ 400.7 $ 373.4 7% Net Product Revenues Marketed...
Apr 17, 2019Company Ranks 1st Among Midsize Employers in 'Drugs & Biotechnology' IndustryBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it has been ranked fourth on Forbes magazine's 2019 list of "America's Best Midsize Employers," increasing from 51st on last year's...
-
Apr 2, 2019
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday,...
-
Mar 6, 2019
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the Cowen and Company Health Care Conference on...
-
Mar 1, 2019Decision on Marketing Authorization Application Expected Q2 '19
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has...
-
Feb 21, 2019- Total Revenues for 2018 Grow 14% Year-over-Year to $1.5 Billion
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2018 2017 % Change 2018 2017 % Change Total...
-
Feb 7, 2019Reduced Rate of Decline Maintained in Children with CLN2 Disease, a Form of Batten Disease
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that an ongoing open-label extension study treating patients with Brineura® (cerliponase alfa) continued to show a reduced rate of...
-
Feb 4, 2019Presentations to Highlight Results from Studies for the Treatment of Three Forms of MPS and CLN2 Disease, a Form of Batten Disease
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present data in four platform and 10 poster presentations at the 15th Annual WORLDSymposiumTM being held February...
-
Jan 23, 2019
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday,...
-
Jan 7, 2019Completed Enrollment of Subject Cohort to Support BLA Submission Through Accelerated Approval (AA) Pathway for Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a company focused on innovative therapies to treat rare diseases, provided highlights to the investment community on its key milestones for 2019 at the...
-
Dec 18, 2018
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the 37th Annual J.P. Morgan Healthcare Conference...
-
Dec 3, 2018
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the promotion of Amy Wireman to Group Vice President, Human Resources. Ms. Wireman's promotion to lead the Human Resources function...
-
Dec 3, 2018
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will participate in Citi's 13th Annual Biotech Conference on December 5 in New York City. To access the live webcast,...
-
Nov 12, 2018First-of-its-Kind Musical Featuring 25 High-School Students Affected by Bleeding Disorders Premieres in Broadway Theater
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the debut of the Broadway-style 'Hemophilia: The Musical,' a first-of-its-kind theatrical production featuring 25 students affected by a...
-
Nov 8, 2018- Credit Suisse 27th Annual Credit Suisse Healthcare Conference on November 13 in Scottsdale, AZ
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will participate in two investor conferences this November. To access the events that are accessible by live webcasts,...
-
Nov 7, 2018Vosoritide for Achondroplasia: Demonstrates Continued Increased Growth through 42 months in Phase 2; Global Phase 3 Fully Enrolled
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) updated the investment community on the Company's research and development portfolio, which is focused on innovative therapies to treat rare and...
-
Nov 1, 2018Key Research & Development Pipeline Products and Data to be Presented, Including:
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host an R&D Day from 8:30am (ET) to 11:30am (ET) on Wednesday, November 7, 2018 in New York City. BioMarin management and external experts will...
-
Oct 25, 2018- First Nine Months of 2018 Total Revenues Grow 19% Year-over-year to $1.14 Billion
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 % Change 2018 2017 % Change Total...
-
Oct 16, 2018FDA Approval Triggers $15 Million Payment
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Company earned $15 million in milestone payments from Pfizer Inc. These milestone payments were triggered by the U.S. Food and...
-
Oct 11, 2018The young adults, each affected by a bleeding disorder, will perform in the Broadway-style musical upon completion of the 'Breaking Through!' Musical Theater Intensive workshop
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the twenty-five high school students from across the U.S. who will participate in 'Hemophilia: The Musical,' a first-of-its-kind...
-
Oct 11, 2018Company listed amongst top five biotech employers
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that Forbes' named the company to its list, Global 2000: World's Best Employers. It is ranked within the top 300 out of a total of 2000...
-
Oct 4, 2018
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday,...
-
Sep 19, 2018Cantor Fitzgerald Global Healthcare Conference on October 1 in New York City
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will participate in two investor conferences this October. To access the events that are accessible by live webcasts,...
-
Sep 5, 2018Updated results from Phase 1/2 program for tralesinidase alfa (formerly BMN 250)
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present 20 poster presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Symposium...
-
Aug 22, 2018- Citi's 13th Annual Biotech Conference on September 5-6 in Boston
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will participate in three investor conferences this September. To access the events that are accessible by live...
-
Aug 2, 2018- Total Revenues of $372.8 million in the Quarter
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2018 2017 % Change 2018 2017 % Change Total Revenues $ 372.8
-
Jul 11, 2018
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday,...
-
Jul 9, 2018First-of-Its-Kind Musical to Help Empower the Bleeding Disorder Community to Find and Use their Voices through the Power of Music
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced an exclusive partnership with Believe Limited to produce the 'Breaking Through!' musical theater intensive. The first-of-its-kind...
-
Jun 28, 2018Five Students with Rare Genetic Diseases Receive a Total of $20,000 for Higher Education
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that it has awarded the first five recipients of the RARE Scholars program, an annual scholarship for students living with rare disease....
-
Jun 14, 2018
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company dosed the first participant in a global Phase 2 study for vosoritide, an analog of C-type Natriuretic Peptide (CNP), in...
-
Jun 7, 2018
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Company received $20 million in milestone payments from Pfizer Inc. These milestone payments were triggered by the U.S. Food...
-
May 24, 2018First Enzyme Therapy to Treat PKU
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that BioMarin received standard approval from the U.S. Food and Drug Administration (FDA) for Palynziq™ (pegvaliase-pqpz) Injection to...
-
May 22, 2018Eliminated Need for Prophylaxis and No Spontaneous Bleeds in Year 2
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its previously reported results of an open-label Phase 1/2 study of valoctocogene roxaparvovec (formerly BMN 270), an...
-
May 17, 2018Platform Presentation to Highlight Data from Ongoing Phase 1/2 Study to Assess Long-Term Efficacy and Safety of Valoctocogene Roxaparvovec in Severe Hemophilia A
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the company will present data in one platform presentation and three poster presentations at the World Federation of Hemophilia...
-
May 15, 2018
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that it has dosed the first patient in a Phase 1/2 study (BMN 270-203) evaluating its investigational gene therapy, valoctocogene...
-
May 2, 2018- Bank of America Merrill Lynch Health Care Conference on May 15 in Las Vegas
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the Bank of America Merrill Lynch Health Care...
-
May 1, 2018Company Ranks 3rd Among Mid-Size Employers in Biotechnology
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that it has been ranked 51st overall among 500 companies on Forbes magazine's 2018 list of "America's Best Mid-size Employers," and...
-
Apr 25, 2018- Total Revenues Top $373 million in the Quarter; GAAP Net Loss of $44 million; Non-GAAP Income of $21 million
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended March 31, 2018 2017 % Change Total Revenues $ 373.4 $ 303.7 23% Vimizim Net Product Revenues...
-
Apr 24, 2018Less decline in motor and language function compared to historical controls
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the New England Journal of Medicine (NEJM) published updated results from a multi-center, open-label, dose-escalation and ongoing...
-
Apr 18, 2018
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday,...
-
Mar 28, 2018FDA PDUFA Action Date for Pegvaliase is May 25, 2018
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the European Medicines Agency (EMA) has accepted BioMarin's submission of a Marketing Authorization Application (MAA) for...
-
Mar 21, 2018One of the largest gene therapy facilities received Facility of the Year Award for Project Execution from the International Society for Pharmaceutical Engineering
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the International Society for Pharmaceutical Engineering (ISPE) selected the company's gene therapy manufacturing facility as the...
-
Mar 6, 2018- Cowen and Company 38th Annual Health Care Conference on March 13 in Boston
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the Cowen and Company 38th Annual Health Care...
-
Feb 28, 2018Sculpture Unveiled to Honor Rare Disease Patients
BioMarin today announced the launch of RARE Scholars, an annual scholarship for students living with rare disease. RARE Scholars aims to empower patients with continued education by recognizing...
-
Feb 22, 2018- Record Total Revenues of $1.3 Billion for Full Year 2017 Representing an 18% Increase Year over Year
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2017 2016 % Change 2017 2016 % Change Total...
-
Feb 7, 2018Normalization of biomarker and liver size; stabilization of early cognitive effects suggested in preliminary data
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it presented interim data from a Phase 1/2 trial for BMN 250, an investigational enzyme replacement therapy using a novel fusion of...
-
Feb 6, 2018
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that The WORLDSymposium 2018 awarded Brineura® (cerliponase alfa) the New Treatment Award, which recognizes important achievements in...
-
Feb 5, 2018Oral Presentations to Highlight Results from Studies for the Treatment of Sanfilippo Syndrome Type B, Morquio A Syndrome and CLN2 Disease, a Form of Batten Disease
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present data in five oral and 15 poster presentations at the 14th Annual WORLDSymposiumTM being held February 5-9,...
-
Jan 24, 2018
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday,...
-
Jan 3, 2018
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the 36th Annual J.P. Morgan Healthcare Conference on
-
Dec 22, 2017Regulatory Review Process Proceeding In-line with Company's Expectations
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) will require additional time to complete its review of the Biologics License...
-
Dec 19, 2017Second Phase 3 Study, GENEr8-2, to Begin at the Start of 2018
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that it has dosed the first patient in the global GENEr8-1 Phase 3 study with the 6e13 vg/kg dose for valoctocogene roxaparvovec...
-
Dec 11, 2017New 1.5 Year Results Demonstrating 6e13 vg/kg Dose Achieved Sustained Factor VIII Levels within the Normal Range in Severe Hemophilia A for Most Patients
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced updates on valoctocogene roxaparvovec (formerly BMN 270), an investigational gene therapy treatment for severe hemophilia at ASH. Efficacy...
-
Dec 9, 2017Valoctocogene Roxaparvovec Demonstrated Sustained Normal or Near Normal Factor VIII Levels in Severe Hemophilia A for Most Patients at Both Doses in Phase 1/2 Study
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its previously reported results of an open-label Phase 1/2 study of valoctocogene roxaparvovec (formerly BMN 270), an...
-
Dec 6, 2017Oral Presentation to Include 78 Week Data with 6e13 Dose Cohort and 32 Week Data with 4e13 Dose Cohort from its Ongoing Phase 1/2 valoctocogene roxaparvovec (formerly BMN 270) Clinical Program, a Gene Therapy for Hemophilia A
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present data in a late breaking abstract session at the 59th American Society of Hematology (ASH) Annual Meeting &...
-
Nov 27, 2017
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has entered into a definitive agreement to sell the Rare Pediatric Disease Priority Review Voucher (PRV) it obtained in April of...
-
Oct 31, 2017- Credit Suisse's 26th Annual Healthcare Conference on November 7 in Scottsdale, AZ
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in Credit Suisse's 26th Annual Healthcare Conference on November 7, 2017 at 9:10am MT/11:10am ET, in...
-
Oct 26, 2017- Company Announces Total Revenues of $334.1 million in the Third Quarter of 2017; Full-year Revenue Guidance Confirmed at between $1.29 billion and $1.32 billion
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 % Change 2017 2016 % Change Total...
-
Oct 26, 2017Global Phase 3 Program to Begin Before Year End
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the U.S. Food and Drug Administration (FDA) granted valoctocogene roxaparvovec (formerly BMN 270) Breakthrough Therapy Designation....
-
Oct 18, 2017Selection of BMN 290 Next IND Drug Development Candidate for Treatment of Friedreich's Ataxia
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) updated the investment community on the Company's development portfolio, which is focused on innovative therapies to treat rare and ultra-rare diseases....
-
Oct 18, 2017
BioMarin announced today that Brineura® (cerliponase alfa) has been awarded the 2017 Popular Science "Best of What's New" award in the health category. Each year, Popular Science reviews...
-
Oct 11, 2017
Key program updates will include the following: BMN 270 gene therapy for hemophilia A: 4e13 dose and Phase 3 Study Design Vosoritide for achondroplasia: long-term extension data Pegvaliase for...
-
Oct 10, 2017
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday,...
-
Oct 3, 2017
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former Baxalta Chief Financial Officer and Chief...
-
Sep 14, 2017Regulatory Review Process Proceeding In-line with Company's Expectations
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has provided the company with the "Day-74" filing communication for its Biologics...
-
Sep 6, 2017Preliminary biomarker and liver size data show marked decreases; early cognitive effects encouraging, pending more mature data
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it presented interim data from the dose escalation arm of a Phase 1/2 trial for BMN 250, an investigational enzyme replacement...
-
Sep 5, 2017
BioMarin (Nasdaq:BMRN) announced that the company will present data in three platform presentations and fifteen poster presentations at the 13th International Congress of Inborn Errors of...
-
Aug 29, 2017
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for pegvaliase,...
-
Aug 23, 2017
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the underwriters of its recently announced public offering of 0.599% senior subordinated convertible notes due 2024 (the Notes)...
-
Aug 21, 2017For the fourth consecutive year, BioMarin ranks in top 20 on list
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that it has been ranked 12th on Forbes magazine's 2017 list of the "World's Most Innovative Companies." BioMarin, a pharmaceutical...
-
Aug 15, 2017- Citi's 12th Annual Biotech Conference on September 6 in Boston
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will participate in Citi's Annual Biotech Conference on September 6, 2017 in Boston, Baird's 2017 Global Healthcare...
-
Aug 7, 2017BioMarin Announces Offering of $450 Million of 0.599% Senior Subordinated Convertible Notes Due 2024
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), announced today an underwritten offering of $450 million aggregate principal amount of 0.599% senior subordinated convertible notes due 2024 (the...
-
Aug 7, 2017
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), announced today an underwritten offering of $450 million aggregate principal amount of senior subordinated convertible notes due 2024 (the Notes)....
-
Aug 2, 2017- Company Announces Record Total BioMarin Revenues of $317.4 million in the Second Quarter of 2017
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2017 2016 % Change 2017 2016 % Change Total BioMarin Revenues
-
Aug 2, 2017- Recent 4e13 vg/kg Data Indicates Majority of Patients in Open-Label Phase 1/2 Study Expected to Achieve Factor VIII Activity Levels in the Normal Range
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that it will expand its development plan for BMN 270, its investigational gene therapy for hemophilia A, to include an additional Phase...
-
Jul 31, 2017- Company to Also Provide Data and Development Plan Update on 4e13 vg/kg Dose of Investigational Gene Therapy Product BMN 270 for Hemophilia A
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday,...
-
Jul 18, 2017
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday,...
-
Jul 18, 2017-- Agreement terms resolve global patent proceedings regarding Sarepta’s sale of EXONDYS 51® (etep-lirsen) and future Duchenne muscular dystrophy (DMD) exon-skipping products --
CAMBRIDGE, Mass. and SAN RAFAEL, Calif., July 18, 2017 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of...
-
Jul 11, 2017
BioMarin Provides BMN 270 Data at International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress Initiation of Phase 3 Registrational Study Planned for Q4 2017 with 6e13 vg/kg Dose 97%...
-
Jun 30, 2017
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that the company submitted a Biologics License Application (BLA) on Friday, June 30, 2017 to the U.S. Food and Drug Administration (FDA) for...
-
Jun 16, 2017Oral Presentation to Include Interim Results from its Ongoing Phase 1/2 BMN 270 Clinical Program, a Gene Therapy for Hemophilia A
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present data in a late breaking abstract session at the International Society on Thrombosis and Haemostasis (ISTH)...
-
Jun 1, 2017Dosing includes all ages from birth for this fatal and rapid pediatric neurodegenerative condition
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the European Commission (EC) has granted marketing authorization for Brineura™ (cerliponase alfa), the first treatment approved in the...
-
May 31, 2017- Goldman Sachs 38th Annual Global Healthcare Conference on June 13 in Rancho Palos Verdes, CA
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Dan Spiegelman, Executive Vice President and Chief Financial Officer, will participate in the Goldman Sachs 38th Annual Global...
-
May 4, 2017- First Quarter 2017 Total BioMarin Revenues Increase 28% Year over Year to $304 million
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended March 31, 2017 2016 % Change Total BioMarin Revenues $ 304 $ 237 28 % Aldurazyme Net Product...
-
May 2, 2017- Deutsche Bank's 42nd Annual Health Care Conference on May 3 in Boston
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in Deutsche Bank's 42nd Annual Health Care...
-
Apr 27, 2017Brineura™ is the first FDA-approved treatment for this fatal neurodegenerative condition
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the U.S. Food and Drug Administration (FDA) approved Brineura™ (cerliponase alfa) to slow the loss of ambulation in symptomatic...
-
Apr 21, 2017One of the First Therapies to Receive Positive CHMP Opinion Using New Accelerated Assessment Process
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has...
-
Apr 20, 2017
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, May...
-
Apr 13, 2017Retains exclusive U.S. rights until October 1, 2020
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that it has entered into a settlement agreement with Par Pharmaceutical that resolves patent litigation in the United States (U.S.)...
-
Feb 23, 2017- Full Year 2016 Total BioMarin Revenues Increase 26% Year over Year to $1.12 billion
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2016 2015 % Change 2016 2015 % Change Total...
-
Feb 15, 2017Oral Presentations to Include Research and Data in Ongoing Studies for the Treatment of Morquio A Syndrome and CLN2 Disease, a Form of Batten Disease
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present data in four oral and seven poster presentations at the 13th Annual WORLDSymposium™ being held February...
-
Feb 8, 2017- Leerink Partners 6th Annual Global Healthcare Conference on February 16 in New York City
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the Leerink Partners 6th Annual Global...
-
Feb 7, 2017
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday,...
-
Feb 1, 2017First Product to be Eligible for Access to PRIME in Hemophilia
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the European Medicines Agency (EMA) has granted access to its Priority Medicines (PRIME) regulatory initiative for the company's...
-
Jan 8, 2017Factor VIII Levels Maintained for All High Dose Patients at 34-50 Weeks
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today an update to its positive interim results of an open-label Phase 1/2 study of BMN 270, an investigational gene therapy treatment for...
-
Jan 3, 2017
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the 35th Annual J.P. Morgan Healthcare Conference on
-
Dec 12, 2016
SAN RAFAEL, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has initiated a global Phase 3 study for vosoritide, an analog of...
-
Nov 3, 2016Credit Suisse 25th Annual Healthcare Conference on November 7 in Scottsdale, Arizona
SAN RAFAEL, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will...
-
Oct 27, 2016Third Quarter 2016 Total BioMarin Revenues Increase 34% Year over Year to $280 million
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 % Change 2016 2015 % Change Total...
-
Oct 19, 2016Highest Dose (30 µg/kg/day) Shows Approximately 50% Increase in Mean Annualized Growth Velocity, Comparable with 15 µg/kg/day dose
SAN RAFAEL, Calif., Oct. 19, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today provided an update on its Phase 2 study of vosoritide, an analog of C-type Natriuretic...
